Artículo
Implementing Standard Diagnosis and Treatment for Locally Advanced Breast Cancer Through Global Research in Latin America: Results From a Multicountry Pragmatic Trial
Retamales, Javier; Daneri Navarro, Adrián; Artagaveytia, Nora; Alves Da Quinta, Daniela Belén
; Abdelhay, Eliana; Podhajcer, Osvaldo Luis
; Velázquez, Carlos; Giunta, Diego Hernan
; Crocamo, Susanne; Garibay Escobar, Adriana; Del Toro Arreola, Alicia; Rodriguez, Robinson; Aghazarian, Marta; Alcoba, Elsa; Alonso, Isabel; Binato, Renata; Bravo, Alicia I.; Canton Romero, Juan; Carraro, Dirce M.; Castro, Mónica; Castro Cervantes, Juan; Cataldi, Sandra; Camejo, Natalia; Cortes Sanabria, Laura; Valenzuela Antelo, Olivia; Venegas Godinez, Laura; Zagame, Livia; Gomez, Jorge; Llera, Andrea Sabina
; Müller, Bettina
Fecha de publicación:
05/2024
Editorial:
American Society of Clinical Oncology
Revista:
JCO Global Oncology
ISSN:
2687-8941
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Purpose Breast cancer mortality rates in Latin America (LA) are higher than those in the United States, possibly because of advanced disease presentation, health care disparities, or unfavorable molecular subtypes. The Latin American Cancer Research Network was established to address these challenges and to promote collaborative clinical research. The Molecular Profiling of Breast Cancer Study (MPBCS) aimed to evaluate the clinical characteristics and treatment outcomes of LA participants with locally advanced breast cancer (LABC). Patients and Methods The MPBCS enrolled 1,449 participants from Argentina, Brazil, Chile, Mexico, and Uruguay. Through harmonized procedures and quality assurance measures, this study evaluated clinicopathologic characteristics, neoadjuvant chemotherapy response, and survival outcomes according to residual cancer burden (RCB) and the type of surgery. Results Overall, 711 and 480 participants in the primary surgery and neoadjuvant arms, respectively, completed the 5-year follow-up period. Overall survival was independently associated with RCB (worse survival for RCBIII-adjusted hazard ratio, 8.19, P < .001, and RCBII [adjusted hazard ratio, 3.69, P < .008] compared with RCB0 [pathologic complete response or pCR]) and type of surgery (worse survival in mastectomy than in breast-conserving surgery [BCS], adjusted hazard ratio, 2.97, P = .001). The hormone receptor–negative-human epidermal growth factor receptor 2–positive group had the highest proportion of pCR (48.9%). The analysis of the ASCO Quality Oncology Practice Initiative breast module revealed high compliance with pathologic standards but lower adherence to treatment administration standards. Notably, compliance with trastuzumab administration varied widely among countries (33.3%-88.7%). Conclusion In LABC, we demonstrated the survival benefit of BCS and the prognostic effect of the response to available neoadjuvant treatments despite an important variability in access to key treatments. The MPBCS represents a significant step forward in understanding the real-world implementation of oncologic procedures in LA.
Palabras clave:
Breast cancer
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Retamales, Javier; Daneri Navarro, Adrián; Artagaveytia, Nora; Alves Da Quinta, Daniela Belén; Abdelhay, Eliana; et al.; Implementing Standard Diagnosis and Treatment for Locally Advanced Breast Cancer Through Global Research in Latin America: Results From a Multicountry Pragmatic Trial; American Society of Clinical Oncology; JCO Global Oncology; 10; 5-2024; 1-15
Compartir
Altmétricas